Analysts See $-1.60 EPS for Agios Pharmaceuticals, Inc. (AGIO)

April 21, 2018 - By Ellis Scott

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) LogoInvestors sentiment increased to 1.22 in Q4 2017. Its up 0.01, from 1.21 in 2017Q3. It improved, as 19 investors sold Agios Pharmaceuticals, Inc. shares while 48 reduced holdings. 27 funds opened positions while 55 raised stakes. 45.70 million shares or 2.27% more from 44.69 million shares in 2017Q3 were reported.
Wells Fargo And Mn holds 0% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 71,065 shares. Fernwood Investment Mngmt has 27,550 shares for 0.84% of their portfolio. State Street invested 0.01% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Fifth Third Bankshares accumulated 155 shares. Principal Gp Incorporated invested in 0% or 13,362 shares. Capital Ww accumulated 0.01% or 663,000 shares. Massachusetts-based Weiss Asset L P has invested 0.04% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Capital Ca has invested 0.23% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Voya Management Limited Liability Corporation has invested 0% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Trexquant Inv Limited Partnership reported 0.02% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Vanguard Gru invested in 0.01% or 3.30 million shares. Moreover, Guggenheim Ltd Limited Liability Company has 0.01% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 51,064 shares. Geode Mgmt Limited Liability Com has invested 0.01% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Ubs Asset Mngmt Americas owns 345,284 shares. Blackrock accumulated 2.81M shares or 0.01% of the stock.

Since January 10, 2018, it had 1 insider purchase, and 20 insider sales for $17.04 million activity. 2,000 shares were sold by Bowden Christopher, worth $157,500. On Wednesday, January 24 the insider Schenkein David P sold $1,600. Another trade for 2,050 shares valued at $173,533 was made by Hoerter Steven L. on Thursday, March 22. Alenson Carman sold $161,250 worth of stock or 2,150 shares. Foster-Cheek Kaye I sold 6,800 shares worth $557,396. Another trade for 200 shares valued at $16,688 was bought by Scadden David.

Analysts expect Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) to report $-1.60 EPS on May, 4 before the open.They anticipate $0.04 EPS change or 2.56 % from last quarter’s $-1.56 EPS. After having $-1.81 EPS previously, Agios Pharmaceuticals, Inc.’s analysts see -11.60 % EPS growth. The stock decreased 2.08% or $1.84 during the last trading session, reaching $86.45. About 324,378 shares traded. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has risen 41.40% since April 21, 2017 and is uptrending. It has outperformed by 29.85% the S&P500.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings Coverage

Among 4 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Agios Pharmaceuticals had 7 analyst reports since November 2, 2017 according to SRatingsIntel. As per Wednesday, November 1, the company rating was maintained by RBC Capital Markets. JP Morgan maintained the shares of AGIO in report on Thursday, February 15 with “Overweight” rating. The stock has “Buy” rating by Credit Suisse on Thursday, February 15. SunTrust maintained the stock with “Buy” rating in Sunday, November 19 report. The stock has “Outperform” rating by Credit Suisse on Wednesday, April 11. Credit Suisse maintained the stock with “Outperform” rating in Thursday, November 2 report. The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) earned “Buy” rating by RBC Capital Markets on Wednesday, February 14.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company has market cap of $4.96 billion. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. It currently has negative earnings. The firm is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.